论文部分内容阅读
目的:研究EphA4在卵巢肿瘤组织中的表达,并分析其生物学特性及临床意义。方法:应用免疫组织化学方法检测84例卵巢癌和20例卵巢良性肿瘤组织中EphA4蛋白的表达;应用原位分子杂交法检测上述组织中EphA4mRNA的表达。结果:EphA4蛋白及EphA4mRNA在卵巢癌中的表达明显高于卵巢良性肿瘤(P<0.01);EphA4蛋白和EphA4mRNA的表达在卵巢癌组织学分级,临床分期和淋巴结转移的分组比较中差异具有统计学意义(P<0.05),而与患者的年龄、组织学分型及有无腹水等无关(P>0.05)。结论:EphA4的过表达可能促进卵巢癌的进展和转移,可以作为判断卵巢癌预后的重要指标。
Objective: To study the expression of EphA4 in ovarian tumor and to analyze its biological characteristics and clinical significance. Methods: The expression of EphA4 protein was detected by immunohistochemistry in 84 cases of ovarian cancer and 20 cases of benign ovarian tumors. The expression of EphA4 mRNA in these tissues was detected by in situ hybridization. Results: The expression of EphA4 protein and EphA4 mRNA in ovarian cancer was significantly higher than that in benign ovarian tumor (P <0.01). The expression of EphA4 protein and EphA4 mRNA in ovarian cancer histological grade, clinical stage and lymph node metastasis were statistically different (P <0.05), but not with age, histological type, presence or absence of ascites and so on (P> 0.05). Conclusion: Overexpression of EphA4 may promote the progression and metastasis of ovarian cancer, which may be used as an important index to judge the prognosis of ovarian cancer.